

PROVIDER NOTICE

Provider Relations Department 1-888-895-4998

New Prior Authorization Requirements For Certain Provider-Administered Medications

Effective Date: May 1, 2023

Health Plan(s) Affected: Priority Partners, Johns Hopkins Advantage MD (AMD), and Johns Hopkins US Family Health Plan (USFHP)

Type of Change: Process

Explanation of Change:

Effective May 1, 2023, Johns Hopkins HealthCare will require prior authorization to determine medical necessity for several provider-administered medications under the Priority Partners, USFHP, and Advantage MD health plans. These requirements affect members of all ages.

Prior Authorization Requirements Effective May I

Priority Partners* | Advantage MD* | USFHP*

Additionally, certain medications will require site of care prior authorization review under Priority Partners and USFHP as of May I, 2023. This site of care requirement is noted for the applicable medications in the prior authorization medication lists shown above. These site of care reviews are applicable for new therapy starts, as well as authorization renewals.

The comprehensive lists of provider-administered medications that require prior authorization for these health plans are also available on the <u>JHHC website</u> for your reference.

Submitting Medical Injectable Prior Authorization Requests:

Priority Partners:

- Providers may submit electronic prior authorization requests through NovoLogix using the Priority Partners HealthLINK secure provider portal.
- If HealthLINK is not able to be accessed, a completed Medical Injectable Drug-specific Prior Authorization Form with supportive clinical documentation may be faxed to Priority Partners at: 866-212-4756.

Advantage MD:

- Providers may submit electronic prior authorization requests through NovoLogix using the AMD HealthLINK secure provider portal.
- If HealthLINK is not able to be accessed, contact NovoLogix for assistance by calling: 800-932-7013.

USFHP:

Providers may request prior authorization, by submitting the <u>Medical Injectable Prior</u> <u>Authorization Form*</u> along with clinical supporting documentation via fax to 410-424-2801.



*If the link to this PDF breaks, please visit our <u>Communications Repository</u>